Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:27:50 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:DYN - DYNE THERAPEUTICS INC - http://www.Dynegy.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
DYN - Q0.523.00·25.681.023.65-1.19-4.8976.422,9897,26424.68  25.29  23.5430.2687  6.4016:02:44Mar 2715 min RT 2¢

Recent Trades - Last 10 of 7264
Time ETExPriceChangeVolume
16:02:44Q23.65-1.1717
16:01:45Q23.65-1.17928
16:01:41Q23.65-1.176
16:01:37Q23.65-1.17109
16:01:11Q23.65-1.17272
16:01:00Q23.65-1.176,180
16:00:58Q23.65-1.17270
16:00:48Q23.65-1.17246
16:00:48Q23.65-1.1732
16:00:07Q23.65-1.17118

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-27 16:05U:DYNNews ReleaseDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
2024-03-27 08:30U:DYNNews ReleaseDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
2024-03-25 07:30U:DYNNews ReleaseDyne Therapeutics Announces CEO Transition
2024-03-13 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
2024-03-05 07:30U:DYNNews ReleaseDyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-02-14 16:15U:DYNNews ReleaseDyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
2024-02-01 07:30U:DYNNews ReleaseDyne Therapeutics to Present at February Investor Conferences
2024-01-11 16:05U:DYNNews ReleaseDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2024-01-05 07:30U:DYNNews ReleaseDyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-04 22:47U:DYNNews ReleaseDyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
2024-01-03 16:25U:DYNNews ReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
2024-01-03 06:30U:DYNNews ReleaseDyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE ¢ „ ¢ Platform in Developing Therapeutics for Rare Muscle Diseases
2024-01-02 16:05U:DYNNews ReleaseDyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
2023-11-07 07:30U:DYNNews ReleaseDyne Therapeutics to Present at November Investor Conferences
2023-10-30 07:30U:DYNNews ReleaseDyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
2023-09-28 07:30U:DYNNews ReleaseDyne Therapeutics to Present at October Investor Conferences
2023-09-20 16:05U:DYNNews ReleaseDyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
2023-09-05 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-03 07:30U:DYNNews ReleaseDyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
2023-06-01 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Jefferies Healthcare Conference